// App-Quantinova.ai

618 : Use of the PRO Onc Assay (Prometheus) to measure HER2 overexpression/activation in circulating tumor cells (CTCs) in women with HER2-negative metastatic breast cancer (MBC): A Sarah Cannon Research Institute (SCRI) trial.

Researchers

Presenter

  • John D. Hainsworth

Principal Investigators

  • Howard A. Burris

  • Patrick Brian Murphy

  • Ruth E. Lamar

  • Mythili Shastry

  • Lindsey H. Finney

  • Denise Aysel Yardley

Medical Centers

  • SCRI/Tennessee Oncology, PLLC, Nashville, TN

  • Tennessee Oncology, PLLC/Sarah Cannon Research Institute, Nashville, TN

  • SCRI, Nashville, TN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved